Investments in equity method investees

12 Months Ended

Mar. 31, 2024

Investments in equity method investees

14.

Investments in equity method investees


	Amounts
	RMB
	(in millions)

Balance as of March 31, 2022		219,642
Additions		4,990
Share of results, other comprehensive income and other reserves (i)		677
Disposals		(1,192	)
Distributions (ii)		(11,645	)
Transfers		1,046
Impairment loss (iii)		(8,310	)
Foreign currency translation adjustments		2,172
Balance as of March 31, 2023		207,380
Additions		3,605
Share of results, other comprehensive income and other reserves (i)		2,739
Disposals		(1,069	)
Distributions		(1,258	)
Transfers		32
Impairment loss (iii)		(9,895	)
Foreign currency translation adjustments		1,597
Balance as of March 31, 2024		203,131

(i)

Share of results, other comprehensive income and other reserves include the share of results of the equity method investees, the gain or loss arising from the deemed disposal of the equity method investees and basis differences arising from equity method investees. The amount excludes the expenses relating to the share-based awards underlying the equity of the Company and Ant Group granted to employees of certain equity method investees.

(ii)

Includes dividend declared by Ant Group amounting to RMB10,519 million for the year ended March 31, 2023.

(iii)

Impairment loss recorded represents other-than-temporary decline in fair value below the carrying value of the investments in equity method investees. The valuation inputs for the fair value measurement with respect to the impairments include the stock price for equity method investees that are listed, as well as certain unobservable inputs that are not subject to meaningful aggregation.

As of March 31, 2024, equity method investments with an aggregate carrying amount of RMB26,519 million are publicly traded and the total market value of these investments amounted to RMB28,364 million. As of March 31, 2024, the Company’s retained earnings included undistributed earnings from equity method investees of RMB47,770 million.

14.

Investments in equity method investees (Continued)

For the years ended March 31, 2022, 2023 and 2024, equity method investments held by the Company in aggregate have met the significance criteria as defined under Rule 4-08(g) of Regulation S-X. As such, the Company is required to present summarized financial information for all of its equity method investments as a group as follows:


	Year ended March 31,
	2022			2023			2024
	RMB			RMB			RMB
	(in millions)
Operating data:
Revenue		541,712			441,495			451,861
Cost of revenue		(371,076	)		(297,895	)		(312,422	)
Income from operations		38,006			27,163			56,646
Net income (loss)		113,970			(86,761	)		75,820


	As of March 31,
	2023		2024
	RMB		RMB
	(in millions)
Balance sheet data:
Current assets		591,660		619,857
Non-current assets		803,288		788,137
Current liabilities		409,055		469,259
Non-current liabilities		115,399		83,997
Noncontrolling interests and mezzanine equity		14,023		13,863